

## Long-Term Performance of Y&P BioPharma Indices

• Over the long term, the NBI has outperformed both the U.S. and Euro Biopharma indices as well as the broader market indices, including recently.



# BioPharma Drug Comparative LTM P/E Ratios


• The average P/E ratios of the companies in the Y&P U.S. BioPharma Index and the Y&P European Pharma Index increased.



(1) As of March 31, 2024

## Y&P BioPharma Indices – First Quarter of 2024

• In the first quarter of 2024, the NBI underperformed the Y&P U.S. BioPharma and Euro BioPharma indices and the market indices.



## Y&P Biotechnology Indices – First Quarter of 2024

However, the Y&P Medium and Small Cap biotech index performed well.

